Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

Next Previous
Trial Profile

A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms R-MegaCHOEP

Most Recent Events

  • 01 May 2024 Results investigating the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years, published in the Leukemia
  • 13 Mar 2020 Results comparing International prognostic indices in diffuse large B-cell lymphoma using different trials published in the Blood
  • 06 Nov 2019 Results of 10-year follow-up of this study, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top